Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    Pfizer Inc. (PFE) Insider Trading Activity

    Healthcare • Drug Manufacturers - General • 88,000 employees

    Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

    Total Value

    $8,364,610.75

    Total Shares

    81,801

    Average Trade Value

    $160,857.90

    Most Active Insider

    Bourla Albert

    Total Activity: $45,922,352

    Largest Single Transaction

    $18,248,188

    by Bourla Albert on Feb 27, 2025

    30-Day Activity

    0 Transactions

    Volume: 0 shares
    Value: $0

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    Executive Vice President
    Officer
    Feb 27, 2025 48,419 $1,515,999 122,413 (+39.6%) Exercise/Conversion
    Executive Vice President
    Officer
    Feb 27, 2025 1,683 $43,926 109,851 (-1.5%) Payment of Exercise Price
    Executive Vice President
    Officer
    Feb 27, 2025 468 $12,215 43,774 (-1.1%) Payment of Exercise Price
    Executive Vice President
    Officer
    Feb 27, 2025 17,846 $465,067 25,928 (-68.8%) Payment of Exercise Price
    Executive Vice President
    Officer
    Feb 27, 2025 19,054 $596,581 44,242 (+43.1%) Exercise/Conversion
    Executive Vice President
    Officer
    Feb 27, 2025 45,347 $1,181,743 75,958 (-59.7%) Payment of Exercise Price
    Executive Vice President
    Officer
    Feb 27, 2025 1,108 $28,919 121,305 (-0.9%) Payment of Exercise Price
    President, Rd
    Officer
    Feb 27, 2025 17,450 $10,000 172,147 (+10.1%) Grant
    President, Rd
    Officer
    Feb 27, 2025 8,909 $232,525 163,238 (-5.5%) Payment of Exercise Price
    Executive Vice President
    Officer
    Feb 27, 2025 2,178 $56,846 248,688 (-0.9%) Payment of Exercise Price
    Executive Vice President
    Officer
    Feb 27, 2025 79,779 $2,079,041 168,909 (-47.2%) Payment of Exercise Price
    Executive Vice President
    Officer
    Feb 27, 2025 85,182 $2,667,048 250,866 (+34.0%) Exercise/Conversion
    Chairman CEO
    Director, Officer
    Feb 27, 2025 582,823 $18,248,188 931,744 (+62.6%) Exercise/Conversion
    SVP Controller
    Officer
    Feb 27, 2025 553 $14,433 30,510 (-1.8%) Payment of Exercise Price
    Chairman CEO
    Director, Officer
    Feb 27, 2025 18,300 $477,630 913,444 (-2.0%) Payment of Exercise Price
    Chairman CEO
    Director, Officer
    Feb 27, 2025 545,855 $14,224,981 367,589 (-148.5%) Payment of Exercise Price
    Executive Vice President
    Officer
    Feb 27, 2025 146,961 $3,829,804 159,240 (-92.3%) Payment of Exercise Price
    SVP Controller
    Officer
    Feb 27, 2025 22,416 $701,845 31,063 (+72.2%) Exercise/Conversion
    Executive Vice President
    Officer
    Feb 27, 2025 156,914 $4,912,977 309,790 (+50.7%) Exercise/Conversion
    SVP Controller
    Officer
    Feb 27, 2025 20,994 $547,104 9,516 (-220.6%) Payment of Exercise Price
    Executive Vice President
    Officer
    Feb 27, 2025 3,589 $93,673 306,201 (-1.2%) Payment of Exercise Price
    Executive Vice President
    Officer
    Feb 27, 2025 68,022 $1,772,653 41,829 (-162.6%) Payment of Exercise Price
    Executive Vice President
    Officer
    Feb 27, 2025 72,629 $2,274,014 111,534 (+65.1%) Exercise/Conversion
    President, Rd
    Officer
    Feb 26, 2025 9,687 $10,000 159,972 (+6.1%) Grant
    Executive Vice President
    Officer
    Feb 26, 2025 3,220 $85,072 73,994 (-4.4%) Payment of Exercise Price
    President, Rd
    Officer
    Feb 26, 2025 4,872 $128,718 155,100 (-3.1%) Payment of Exercise Price
    SVP Controller
    Officer
    Feb 23, 2025 390 $10,257 9,024 (-4.3%) Payment of Exercise Price
    President, Rd
    Officer
    Feb 23, 2025 662 $17,411 150,285 (-0.4%) Payment of Exercise Price
    Executive Vice President
    Officer
    Feb 22, 2025 11,343 $295,825 25,188 (-45.0%) Payment of Exercise Price
    SVP Controller
    Officer
    Feb 22, 2025 8,741 $263,716 17,602 (+49.7%) Exercise/Conversion
    SVP Controller
    Officer
    Feb 22, 2025 390 $10,257 17,212 (-2.3%) Payment of Exercise Price
    Executive Vice President
    Officer
    Feb 22, 2025 497 $13,071 87,139 (-0.6%) Payment of Exercise Price
    SVP Controller
    Officer
    Feb 22, 2025 7,798 $203,372 9,414 (-82.8%) Payment of Exercise Price
    Executive Vice President
    Officer
    Feb 22, 2025 11,125 $335,641 87,636 (+12.7%) Exercise/Conversion
    Executive Vice President
    Officer
    Feb 22, 2025 9,925 $258,844 77,214 (-12.9%) Payment of Exercise Price
    Executive Vice President
    Officer
    Feb 22, 2025 63,573 $1,917,997 225,184 (+28.2%) Exercise/Conversion
    Executive Vice President
    Officer
    Feb 22, 2025 2,785 $73,246 222,399 (-1.3%) Payment of Exercise Price
    Executive Vice President
    Officer
    Feb 22, 2025 56,715 $1,479,127 165,684 (-34.2%) Payment of Exercise Price
    Executive Vice President
    Officer
    Feb 22, 2025 85,824 $2,589,310 232,775 (+36.9%) Exercise/Conversion
    Chairman CEO
    Director, Officer
    Feb 22, 2025 238,399 $7,192,498 570,436 (+41.8%) Exercise/Conversion
    Executive Vice President
    Officer
    Feb 22, 2025 3,334 $87,684 229,441 (-1.5%) Payment of Exercise Price
    Executive Vice President
    Officer
    Feb 22, 2025 76,565 $1,996,815 152,876 (-50.1%) Payment of Exercise Price
    Chairman CEO
    Director, Officer
    Feb 22, 2025 8,835 $232,361 561,601 (-1.6%) Payment of Exercise Price
    Chairman CEO
    Director, Officer
    Feb 22, 2025 212,680 $5,546,694 348,921 (-61.0%) Payment of Exercise Price
    President, Rd
    Officer
    Feb 22, 2025 7,798 $203,372 150,947 (-5.2%) Payment of Exercise Price
    President, Rd
    Officer
    Feb 22, 2025 340 $8,942 158,745 (-0.2%) Payment of Exercise Price
    President, Rd
    Officer
    Feb 22, 2025 8,741 $263,716 159,085 (+5.5%) Exercise/Conversion
    Executive Vice President
    Officer
    Feb 22, 2025 12,714 $383,581 37,099 (+34.3%) Exercise/Conversion
    Executive Vice President
    Officer
    Feb 22, 2025 568 $14,938 36,531 (-1.6%) Payment of Exercise Price
    Director
    Feb 13, 2025 19,457 $499,072 27,707 (+70.2%) Purchase
    President, Rd
    Officer
    Jan 31, 2025 12,038 $319,248 150,344 (-8.0%) Payment of Exercise Price
    Director
    Oct 30, 2024 1,000 $28,240 10,000 (+10.0%) Purchase